Updates from guardian™ : a comprehensive registration programme

Updates from guardian™ : a comprehensive registration programme

Margareth C. Ozelo

ARTIGO

Inglês

Agradecimentos: Medical writing support was provided by Andy Lockley of Bioscript Medical Ltd (Macclesfield, UK) and funded by Novo Nordisk Health Care AG (Zurich, Switzerland)

Turoctocog alfa is an approved B‐domain truncated recombinant factor VIII concentrate for adults and children with haemophilia A. Clinical data for turoctocog alfa have been reported from the guardian™1, guardian™2 and guardian™3 phase III trials. guardian™1 and guardian™3 phase III trials enrolled...

Fechado

Updates from guardian™ : a comprehensive registration programme

Margareth C. Ozelo


										

Updates from guardian™ : a comprehensive registration programme

Margareth C. Ozelo

    Fontes

    European journal of haematology

    Vol. 95, no. S81, nespSpecial Issue: 12th Novo Nordisk Symposium on Haemostasis Management, Vienna, Austria, 4–6 June 2014 (Dec., 2015), p. 22, n. art. 29